Home › Companies › BLUEPRINT MEDICINES CORP. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BLUEPRINT MEDICINES CORP.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2025: 5 items on BLUEPRINT MEDICINES CORP.’s Form 8-K, filed June 20, 2025: 2 approved · 3 passed (calculated).
Significant dissent: 3 directors (25.8%, 22.4%, 21.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore BLUEPRINT MEDICINES CORP. in the interactive database Compare manager voting policies
These tallies are BLUEPRINT MEDICINES CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffery W. Albers | 44,683,223 | -- | -- | 15,507,415 | 2,342,656 | 74% | Passed (calculated) | — |
| Elect Director: Mark Goldberg, M.D. | 46,734,594 | -- | -- | 13,456,044 | 2,342,656 | 78% | Passed (calculated) | — |
| Elect Director: John Tsai, M.D. | 47,572,890 | -- | -- | 12,617,748 | 2,342,656 | 79% | Passed (calculated) | — |
| 2. Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. | 57,714,069 | 2,450,825 | 25,744 | -- | 2,342,656 | 96% | Approved | — |
| 3. Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025. | 62,209,853 | 288,580 | 34,861 | -- | -- | 99.5% | Approved | — |
Source: BLUEPRINT MEDICINES CORP., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
373 asset managers disclosed a vote on at least one BLUEPRINT MEDICINES CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Jeffrey Albers
BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Jeffery W. Albers”): 44,683,223 for, 15,507,415 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 102 asset managers below reported 28,128,126 for, 5,085,675 withheld, 519,354 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,346,069 | 0 | 0 | 2,400 | For |
| T. Rowe Price | 5,315,475 | 0 | 0 | 21,550 | For |
| BlackRock | 2,524,631 | 0 | 0 | 0 | For |
| Fidelity | 2,339,724 | 0 | 0 | 200 | For |
| JPMorgan | 2,017,498 | 0 | 0 | 0 | For |
| State Street | 3,339 | 0 | 0 | 1,158,395 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 955,278 | Withhold |
| MUTUAL FUND SERIES TRUST | 859,462 | 0 | 0 | 0 | For |
| Invesco | 621,899 | 0 | 0 | 0 | For |
| Charles Schwab | 604,993 | 0 | 0 | 0 | For |
| TIAA | 543,580 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 519,074 | 0 | 0 | 0 | For |
| Jackson National | 381,683 | 0 | 112,784 | 0 | Mixed |
| ACAP Strategic Fund | 0 | 0 | 0 | 444,988 | Withhold |
| AllianceBernstein | 382,517 | 0 | 0 | 0 | For |
| Capital Group | 367,124 | 0 | 0 | 0 | For |
| Legg Mason | 342,300 | 0 | 0 | 3,400 | For |
| American Century | 0 | 0 | 0 | 342,227 | Withhold |
| Columbia Threadneedle | 336,059 | 0 | 0 | 0 | For |
| Goldman Sachs | 291,734 | 0 | 0 | 20,507 | Mixed |
| WILLIAM BLAIR FUNDS | 0 | 0 | 0 | 298,044 | Withhold |
| Equitable | 271,202 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 260,458 | Withhold |
| Principal | 77,655 | 0 | 0 | 148,280 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 207,703 | 0 | 0 | 0 | For |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: John Tsai, M.D.
BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: John Tsai, M.D.”): 47,572,890 for, 12,617,748 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 102 asset managers below reported 29,526,743 for, 3,707,678 withheld, 498,734 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,346,069 | 0 | 0 | 2,400 | For |
| T. Rowe Price | 5,315,475 | 0 | 0 | 21,550 | For |
| BlackRock | 2,524,631 | 0 | 0 | 0 | For |
| Fidelity | 2,339,724 | 0 | 0 | 200 | For |
| JPMorgan | 2,017,498 | 0 | 0 | 0 | For |
| State Street | 1,160,253 | 0 | 0 | 1,481 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 955,278 | Withhold |
| MUTUAL FUND SERIES TRUST | 859,462 | 0 | 0 | 0 | For |
| Invesco | 621,899 | 0 | 0 | 0 | For |
| Charles Schwab | 604,993 | 0 | 0 | 0 | For |
| TIAA | 543,580 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 519,074 | 0 | 0 | 0 | For |
| Jackson National | 381,683 | 0 | 112,784 | 0 | Mixed |
| ACAP Strategic Fund | 0 | 0 | 0 | 444,988 | Withhold |
| AllianceBernstein | 382,517 | 0 | 0 | 0 | For |
| Capital Group | 367,124 | 0 | 0 | 0 | For |
| Legg Mason | 342,300 | 0 | 0 | 3,400 | For |
| American Century | 0 | 0 | 0 | 342,227 | Withhold |
| Columbia Threadneedle | 336,059 | 0 | 0 | 0 | For |
| Goldman Sachs | 291,734 | 0 | 0 | 20,507 | Mixed |
| WILLIAM BLAIR FUNDS | 0 | 0 | 0 | 298,044 | Withhold |
| Equitable | 271,202 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 260,458 | Withhold |
| Principal | 77,655 | 0 | 0 | 148,280 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 207,703 | 0 | 0 | 0 | For |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Mark Goldberg, M.D.
BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Mark Goldberg, M.D.”): 46,734,594 for, 13,456,044 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 102 asset managers below reported 29,487,026 for, 3,726,775 withheld, 519,354 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,346,069 | 0 | 0 | 2,400 | For |
| T. Rowe Price | 5,315,475 | 0 | 0 | 21,550 | For |
| BlackRock | 2,524,631 | 0 | 0 | 0 | For |
| Fidelity | 2,339,724 | 0 | 0 | 200 | For |
| JPMorgan | 2,017,498 | 0 | 0 | 0 | For |
| State Street | 1,160,253 | 0 | 0 | 1,481 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 955,278 | Withhold |
| MUTUAL FUND SERIES TRUST | 859,462 | 0 | 0 | 0 | For |
| Invesco | 621,899 | 0 | 0 | 0 | For |
| Charles Schwab | 604,993 | 0 | 0 | 0 | For |
| TIAA | 543,580 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 519,074 | 0 | 0 | 0 | For |
| Jackson National | 381,683 | 0 | 112,784 | 0 | Mixed |
| ACAP Strategic Fund | 0 | 0 | 0 | 444,988 | Withhold |
| AllianceBernstein | 382,517 | 0 | 0 | 0 | For |
| Capital Group | 367,124 | 0 | 0 | 0 | For |
| Legg Mason | 342,300 | 0 | 0 | 3,400 | For |
| American Century | 0 | 0 | 0 | 342,227 | Withhold |
| Columbia Threadneedle | 336,059 | 0 | 0 | 0 | For |
| Goldman Sachs | 291,734 | 0 | 0 | 20,507 | Mixed |
| WILLIAM BLAIR FUNDS | 0 | 0 | 0 | 298,044 | Withhold |
| Equitable | 271,202 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 260,458 | Withhold |
| Principal | 77,655 | 0 | 0 | 148,280 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 207,703 | 0 | 0 | 0 | For |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 97.7% for (June 12, 2024 meeting) ▼ 1.8 pts
Description as filed by funds: APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.
BLUEPRINT MEDICINES CORP.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 57,714,069 for, 2,450,825 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,348,466 | 3 | 0 | 0 | For |
| T. Rowe Price | 5,337,025 | 0 | 0 | 0 | For |
| BlackRock | 2,524,631 | 0 | 0 | 0 | For |
| Fidelity | 2,339,924 | 0 | 0 | 0 | For |
| JPMorgan | 2,017,498 | 0 | 0 | 0 | For |
| State Street | 1,160,241 | 1,493 | 0 | 0 | For |
| Delaware/Macquarie | 955,278 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 859,462 | 0 | 0 | 0 | For |
| Invesco | 0 | 621,899 | 0 | 0 | Against |
| Charles Schwab | 604,993 | 0 | 0 | 0 | For |
| TIAA | 543,580 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 519,074 | 0 | 0 | 0 | For |
| Jackson National | 370,266 | 124,201 | 0 | 0 | Mixed |
| ACAP Strategic Fund | 444,988 | 0 | 0 | 0 | For |
| AllianceBernstein | 382,517 | 0 | 0 | 0 | For |
| Capital Group | 367,124 | 0 | 0 | 0 | For |
| Legg Mason | 345,700 | 0 | 0 | 0 | For |
| American Century | 0 | 342,227 | 0 | 0 | Against |
| Columbia Threadneedle | 336,059 | 0 | 0 | 0 | For |
| Goldman Sachs | 312,241 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 298,044 | 0 | 0 | 0 | For |
| Equitable | 271,202 | 0 | 0 | 0 | For |
| MFS | 260,458 | 0 | 0 | 0 | For |
| Principal | 225,935 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,703 | 0 | 0 | 0 | For |
Fund voting reports, all 102 managers: 32,444,098 for, 1,244,963 against, 19,018 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,650,806 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 3,863,022 | 0 | 0 | 0 | For |
| JPMorgan | 2,968,883 | 0 | 0 | 0 | For |
| Wellington | 2,595,811 | 0 | 0 | 0 | For |
| State Street | 2,402,619 | 2,420 | 0 | 0 | For |
| BlackRock | 2,318,159 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,532,467 | 0 | 0 | 0 | For |
| Fidelity | 1,255,565 | 0 | 0 | 0 | For |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1,228,220 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,167,237 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,094,841 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 889,570 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 865,256 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 772,960 | 0 | 0 | 0 | For |
| Invesco | 0 | 740,036 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 673,915 | 0 | 0 | 0 | For |
| American Century | 0 | 628,907 | 0 | 0 | Against |
| Siren, L.L.C. | 623,870 | 0 | 0 | 0 | For |
| Charles Schwab | 617,403 | 0 | 0 | 0 | For |
| Nuveen | 590,204 | 0 | 0 | 0 | For |
| Northern Trust | 497,330 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 488,364 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 445,736 | 0 | 0 | 0 | For |
| Woodline Partners LP | 418,873 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 367,124 | 0 | 0 | 0 | For |
Institutional-manager reports, all 296 managers: 43,292,631 for, 1,841,469 against, 25,100 withheld, 1,490 abstained, 1,659 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.5% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
BLUEPRINT MEDICINES CORP.’s own tally for this item (“3. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025.”): 62,209,853 for, 288,580 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 33,702,990 for, 12,323 against, 19,018 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,348,469 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,337,025 | 0 | 0 | 0 | For |
| BlackRock | 2,524,631 | 0 | 0 | 0 | For |
| Fidelity | 2,339,924 | 0 | 0 | 0 | For |
| JPMorgan | 2,017,498 | 0 | 0 | 0 | For |
| State Street | 1,161,666 | 68 | 0 | 0 | For |
| Delaware/Macquarie | 955,278 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 859,462 | 0 | 0 | 0 | For |
| Invesco | 621,899 | 0 | 0 | 0 | For |
| Charles Schwab | 604,993 | 0 | 0 | 0 | For |
| TIAA | 543,580 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 519,074 | 0 | 0 | 0 | For |
| Jackson National | 494,467 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 444,988 | 0 | 0 | 0 | For |
| AllianceBernstein | 382,517 | 0 | 0 | 0 | For |
| Capital Group | 367,124 | 0 | 0 | 0 | For |
| Legg Mason | 345,700 | 0 | 0 | 0 | For |
| American Century | 342,227 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 336,059 | 0 | 0 | 0 | For |
| Goldman Sachs | 312,241 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 298,044 | 0 | 0 | 0 | For |
| Equitable | 271,202 | 0 | 0 | 0 | For |
| MFS | 260,458 | 0 | 0 | 0 | For |
| Principal | 225,935 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,703 | 0 | 0 | 0 | For |
Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 64,582,163 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.93% |
| 2 | T. Rowe Price | 8.26% |
| 3 | BlackRock | 3.91% |
| 4 | Fidelity | 3.62% |
| 5 | JPMorgan | 3.12% |
| 6 | State Street | 1.80% |
| 7 | Delaware/Macquarie | 1.48% |
| 8 | MUTUAL FUND SERIES TRUST | 1.33% |
| 9 | Invesco | 0.96% |
| 10 | Charles Schwab | 0.94% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 11.85% |
| 2 | Avoro Capital Advisors LLC | 5.98% |
| 3 | JPMorgan | 4.60% |
| 4 | Wellington | 4.02% |
| 5 | State Street | 3.72% |
| 6 | BlackRock | 3.59% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.37% |
| 8 | Fidelity | 1.94% |
| 9 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.90% |
| 10 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1.81% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 6,710,708 | 10.39% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 6,640,523 | 10.28% | Form 13F, quarter ended March 31, 2025 |
| T. Rowe Price | 5,415,837 | 8.39% | Form 13F, quarter ended March 31, 2025 |
| Pentwater Capital Management LP | 3,900,000 | 6.04% | Schedule 13G, filed August 14, 2025 |
| Wellington Management | 3,073,306 | 4.76% | Form 13F, quarter ended March 31, 2025 |
| State Street | 2,684,117 | 4.16% | Form 13F, quarter ended March 31, 2025 |
| JPMorgan Chase | 2,506,514 | 3.88% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 1,522,647 | 2.36% | Form 13F, quarter ended March 31, 2025 |
| FMR (Fidelity) | 1,433,169 | 2.22% | Form 13F, quarter ended March 31, 2025 |
| Invesco | 984,674 | 1.52% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 64,582,163 shares outstanding, as reported by BLUEPRINT MEDICINES CORP. on its Form 10-Q dated April 29, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BLUEPRINT MEDICINES CORP.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 373 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,534 separate fund positions. On the most widely held item on that ballot — APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE… — BLUEPRINT MEDICINES CORP.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BLUEPRINT MEDICINES CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BLUEPRINT MEDICINES CORP.’s 10-Q dated April 29, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BLUEPRINT MEDICINES CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Proxy Votes Now, “BLUEPRINT MEDICINES CORP. 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/blueprint-medicines-corp/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.